Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence (NALAPZ)
This study is currently recruiting participants.
Verified by National Institute on Alcohol Abuse and Alcoholism (NIAAA), October 2008
Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ClinicalTrials.gov Identifier: NCT00667875
  Purpose

The principal aim of this exploratory study is to examine whether the addition of aripiprazole to naltrexone will enhance efficacy over naltrexone alone in a 16-week randomized, placebo-controlled clinical trial, in which all subjects will be provided medical management as delivered in the COMBINE Study (Anton et al, 2006). To test whether medication treatment will reduce drinking compared to placebo treatment alone in the context of medical management and whether naltrexone plus aripiprazole will reduce drinking compared to naltrexone treatment alone in the context of medical management.


Condition Intervention Phase
Alcohol Dependence
Drug: Placebo
Drug: Naltrexone
Drug: Naltrexone + Aripiprazole
Phase II

MedlinePlus related topics: Alcoholism
Drug Information available for: Aripiprazole Naltrexone Naltrexone hydrochloride Ethanol
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Factorial Assignment, Safety/Efficacy Study
Official Title: An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence

Further study details as provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):

Primary Outcome Measures:
  • drinks per drinking day [ Time Frame: 16-week treatment period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pill counts and urinary riboflavin levels during treatment [ Time Frame: 16-week ] [ Designated as safety issue: No ]
  • Subject-reported adverse events on the SAFTEE interview [ Time Frame: 16-week ] [ Designated as safety issue: Yes ]
  • Percent heavy drinking days over the 16-week study [ Time Frame: 16-weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: April 2008
Estimated Study Completion Date: April 2010
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Placebo Comparator Drug: Placebo
placebo
2: Active Comparator
Naltrexone
Drug: Naltrexone
Naltrexone (25mg or 50 mg per titration schedule)
3: Active Comparator
Naltrexone + Aripiprazole
Drug: Naltrexone + Aripiprazole
Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 70
  2. Subjects will meet criteria for primary alcohol dependence operationalized as follows:

    A. Meets the DSM IV criteria for alcohol dependence including loss of control over drinking (criterion 3) B. Has not had more than one previous inpatient medical detoxification

  3. Consumes, on average, at least 10 standard drinks per drinking day for men and 8 drinks per day for women in the 90 days pre-screening (to select an appropriately heavy drinking population)
  4. Able to maintain sobriety for four days (with or without the aid of alcohol detoxification medications) as determined by self report, collateral report, and breathalyzer measurements
  5. Able to read and understand questionnaires and informed consent
  6. Lives within approximately 50 miles of the study site -

Exclusion Criteria:

  1. Currently meets DSM IV criteria for any other psychoactive substance dependency disorder except nicotine dependence
  2. Ever abused opiates
  3. Any psychoactive substance abuse, except marijuana and nicotine, within the last 30 days as evidenced by subject report, collateral report, or urine drug screen
  4. Meets DSM IV criteria for current axis I disorders of major depression, panic disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic disorder or organic mental disorder
  5. Meets DSM IV current criteria for dissociative disorder or eating disorders
  6. Has current suicidal ideation or homicidal ideation
  7. Need for maintenance or acute treatment with any psychoactive medication including anti-seizure medications
  8. Current use of disulfiram
  9. Clinically significant medical problems such as cardiovascular, renal, GI, or endocrine problem that would impair participation or limit medication ingestion
  10. Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 3.0 times normal at screening and/or after 5 days abstinence
  11. Sexually active female of child-bearing potential who is pregnant (by urine HCG), nursing, or who is not using a reliable form of birth control
  12. Has current charges pending for a violent crime (not including DUI-related offenses)
  13. Does not have a stable living situation and a reliable source of collateral reporting
  14. Has taken an opiate antagonist drug in the last month
  15. Has taken aripiprazole in the last month or has experienced adverse effects from it at any time in the past
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00667875

Contacts
Contact: Alicia M Baros, Ph.D. 843-792-0073 baros@musc.edu
Contact: Patricia K Latham, Ph.D. 843-792-1230 lathampk@musc.edu

Locations
United States, South Carolina
Medical University of South Carolina, Center for Drug and Alcohol Programs Recruiting
Charleston, South Carolina, United States, 29425
Principal Investigator: Raymond F Anton, MD            
Sponsors and Collaborators
  More Information

Responsible Party: Medical University of South Carolina ( Raymond F. Anton, M.D. )
Study ID Numbers: ANTON-1R21AA017525-01, NIH Grant AA017525-01
Study First Received: April 24, 2008
Last Updated: October 2, 2008
ClinicalTrials.gov Identifier: NCT00667875  
Health Authority: United States: Federal Government

Keywords provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):
Alcohol Dependence
Alcoholism
Naltrexone
Aripiprazole
Substance Abuse

Study placed in the following topic categories:
Mental Disorders
Naltrexone
Alcoholism
Substance-Related Disorders
Disorders of Environmental Origin
Alcohol-Related Disorders
Aripiprazole
Ethanol

Additional relevant MeSH terms:
Tranquilizing Agents
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Narcotic Antagonists
Psychotropic Drugs
Central Nervous System Depressants
Peripheral Nervous System Agents
Antipsychotic Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009